Perspective Therapeutics (CATX) Cash & Equivalents (2010 - 2026)

Perspective Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $270.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 27.96% year-over-year to $270.9 million; the TTM figure through Mar 2026 stood at $270.9 million (up 27.96% YoY), while the FY2025 annual figure was $30.6 million, down 50.26% from the prior year.
• Cash & Equivalents came in at $270.9 million for Q1 2026 at Perspective Therapeutics, up from $30.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $270.9 million in Q1 2026 to a low of $9.2 million in Q4 2023.
• A 5-year average of $100.1 million and a median of $55.9 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 1389.18% in 2024 and tumbled 90.01% in 2025, its largest moves.
• Perspective Therapeutics' Cash & Equivalents stood at $21.0 million in 2022, then tumbled by 55.99% to $9.2 million in 2023, then jumped by 566.59% to $61.6 million in 2024, then tumbled by 50.26% to $30.6 million in 2025, then surged by 784.46% to $270.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $270.9 million, $30.6 million, and $26.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison